

Whitney R Steele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1415738/publications.pdf>

Version: 2024-02-01

18
papers

437
citations

840776

11
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

400
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron deficiency in blood donors: analysis of enrollment data from the REDSâ€” Donor Iron Status Evaluation (RISE) study. <i>Transfusion</i> , 2011, 51, 511-522.	1.6	161
2	Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016. <i>Transfusion Medicine Reviews</i> , 2020, 34, 81-93.	2.0	36
3	HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. <i>Blood</i> , 2020, 136, 1351-1358.	1.4	32
4	Creutzfeldtâ€”Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk. <i>Transfusion</i> , 2017, 57, 1875-1878.	1.6	31
5	HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12â€”month deferral policy for men who have sex with men. <i>Transfusion</i> , 2021, 61, 839-850.	1.6	27
6	Prevalence of <sc>human immunodeficiency virus</sc>, <sc>hepatitis B virus,</sc> and <sc>hepatitis C virus</sc> in United States blood donations, 2015 to 2019: The <sc>Transfusionâ€”Transmissible</sc> Infections Monitoring System (<sc>TTIMS</sc>). <i>Transfusion</i> , 2020, 60, 2327-2339.	1.6	23
7	HIV residual risk in Canada under a threeâ€”month deferral for men who have sex with men. <i>Vox Sanguinis</i> , 2020, 115, 133-139.	1.5	22
8	Research initiatives of blood services worldwide in response to the covidâ€”19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 296-304.	1.5	22
9	Changing the deferral for men who have sex with men â€” an improved model to estimate HIV residual risk. <i>Vox Sanguinis</i> , 2019, 114, 666-674.	1.5	17
10	Donors deferred for self-reported Chagas disease history: does it reduce risk?. <i>Transfusion</i> , 2014, 54, 2092-2097.	1.6	13
11	Prevalence, incidence, and risk factors of human immunodeficiency virus infection in blood donors in the Southeastern United States. <i>Transfusion</i> , 2017, 57, 404-411.	1.6	12
12	COVIDâ€”19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors. <i>Transfusion</i> , 2021, 61, 1471-1478.	1.6	9
13	<sc>HIV</sc> residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men. <i>Vox Sanguinis</i> , 2022, 117, 201-207.	1.5	7
14	Frequency of rare, serious donor reactions: International perspective. <i>Transfusion</i> , 2021, 61, 1780-1788.	1.6	6
15	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. <i>Vox Sanguinis</i> , 2022, 117, 476-487.	1.5	5
16	Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: Application of a statistically representative sampling methodology to assess risk in US blood centers. <i>Transfusion</i> , 2020, 60, 1987-1997.	1.6	4
17	Young donor health and safety: are we doing enough?. <i>ISBT Science Series</i> , 2015, 10, 20-25.	1.1	2
18	Effectiveness of the postâ€”donation instruction sheet in conveying information to repeat blood donors. <i>Vox Sanguinis</i> , 2021, 116, 305-312.	1.5	1